BiPAP治疗COPD合并Ⅱ型呼吸衰竭临床分析

Clinic analysis of Bi-level positive air way pressure in treatment of patients with chronic obstructive pulmonary disease combined type Ⅱ respiratory failure

目的探讨双水平无创正压通气(BiPAP)治疗慢性阻塞性肺疾病急性加重(AECOPD)合并Ⅱ型呼吸衰竭的临床疗效。方法选择2014年1月至2014年12月在我院住院治疗的AECOPD合并Ⅱ型呼吸衰竭患者64例,随机分为观察组及对照组,每组32例。所有患者均给予常规对症治疗,观察组患者在此基础上采用BiPAP治疗,比较两组患者的临床疗效。结果两组患者治疗后pH、PaO_2水平均较治疗前有所增加,且观察组患者的增加程度大于对照组;两组RR、HR、PaCO_2水平较治疗前都有所下降,且观察组患者下降程度大于对照组,差异均有统计学意义(P<0.05)。两组患者的血压与治疗前比较,差异无统计学意义;治疗后观察组患者的血压与对照组比较,差异无统计学意义(P>0.05)。结论应用BiPAP治疗慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭,临床疗效显著,可明显改善患者的血气分析指标,值得临床上推广。

Objective To explore the efficacy of BiPAP ventilator on acute exacerbation of chronic obstructive pulmonary disease（AECOPD） combined Type II respiratory failure. Methods Sixty-four cases of AECOPD combined type II respiratory failure patients from January 2014 to December 2014 were randomly divided into observation group and control group, with 32 cases in each group. The patients in control group received conventional therapies, and the patients in observation group received BiPAP therapy based on conventional therapies. The efficacy of the treatment was compared in the two groups. Results After the treatment, the level of pH and PaO2 are both increased in the two groups, and the increasing of them in observation group is higher than that of the control group; the level of RR, HR and PaCO 2 are all decreased in the two groups, and the decreasing of them in observation group are much higher than that of the control group, the difference are all significant （P〈0.05）. The blood pressure in the two groups before and after the treatment have no significant difference （P〉0.05）. Conclusion BiPAP is effective to treat COPD combined Type II respiratory failure, the clinical efficacy is significant and it is worth popularizing and applying.